13,140 Rigel Pharmaceuticals, Inc. $RIGL Shares Bought by Ritholtz Wealth Management

Ritholtz Wealth Management increased its stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) by 13.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,590 shares of the biotechnology company’s stock after buying an additional 13,140 shares during the quarter. Ritholtz Wealth Management owned about 0.58% of Rigel Pharmaceuticals worth $5,180,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. Signature Equity Partners LLC acquired a new position in shares of Rigel Pharmaceuticals in the third quarter valued at about $27,000. Integrated Wealth Concepts LLC purchased a new position in shares of Rigel Pharmaceuticals in the second quarter worth about $38,000. Signaturefd LLC raised its stake in shares of Rigel Pharmaceuticals by 180.0% in the third quarter. Signaturefd LLC now owns 826 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 531 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Rigel Pharmaceuticals during the third quarter worth about $46,000. Finally, Legal & General Group Plc acquired a new stake in shares of Rigel Pharmaceuticals during the second quarter worth about $162,000. 66.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently weighed in on RIGL shares. Cantor Fitzgerald increased their price target on shares of Rigel Pharmaceuticals from $43.00 to $47.00 and gave the stock a “neutral” rating in a report on Friday, November 6th. Citigroup upped their price objective on shares of Rigel Pharmaceuticals from $83.00 to $86.00 and gave the company a “buy” rating in a report on Monday. Piper Sandler reiterated a “neutral” rating and issued a $49.00 price objective (up from $40.00) on shares of Rigel Pharmaceuticals in a research note on Monday, August 17th. Zacks Research lowered shares of Rigel Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Finally, Weiss Ratings cut shares of Rigel Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Rigel Pharmaceuticals has an average rating of “Hold” and an average price target of $66.75.

Get Our Latest Analysis on RIGL

Rigel Pharmaceuticals Price Performance

Shares of RIGL stock opened at $45.69 on Friday. Rigel Pharmaceuticals, Inc. has a 1-year low of $24.95 and a 1-year high of $52.60. The company has a market cap of $860.34 million, a price-to-earnings ratio of 2.95 and a beta of 1.28. The stock has a 50 day simple moving average of $47.52 and a 200-day simple moving average of $37.61.

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.27). The firm had revenue of $80.89 million during the quarter, compared to analyst estimates of $80.00 million. Rigel Pharmaceuticals had a return on equity of 14.89% and a net margin of 106.59%. Analysts anticipate that Rigel Pharmaceuticals, Inc. will post 2.97 earnings per share for the current fiscal year.

About Rigel Pharmaceuticals

(Free Report)

Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes medicines for people with serious hematologic disorders and cancers. Founded in 1996 and based in South San Francisco, California, the company has focused on treatments that target biological pathways involved in disease. Rigel’s marketed products include Tavalisse (fostamatinib), an oral treatment for adults with chronic immune thrombocytopenia who have had an insufficient response to prior treatment, and Rezlidhia (olutasidenib), an oral therapy for certain adults with relapsed or refractory acute myeloid leukemia containing an IDH1 mutation.

See Also

Want to see what other hedge funds are holding RIGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report).

Institutional Ownership by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.